Transcatheter Tricuspid Valve Intervention: Our Experience and the Current Status in the US

Abstract

Severe tricuspid regurgitation (TR) is now widely thought of as a significant contributor to cardiac morbidity and mortality. Neither medical therapy nor conventional surgery is efficacious for most patients. In contrast, with the rapid development of transcatheter tricuspid valve therapies, TR can now be corrected without incurring the risks of conventional surgery, and it is showing promise to improve quality of life and mortality. In this review, we discuss transcatheter tricuspid valve interventions (TTVIs), the current status of clinical trials in the United States, TTVI devices we have used, and our experience.